1. Home
  2. PRME vs RR Comparison

PRME vs RR Comparison

Compare PRME & RR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.02

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo Richtech Robotics Inc. Class B

RR

Richtech Robotics Inc. Class B

HOLD

Current Price

$1.61

Market Cap

614.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
RR
Founded
2019
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
614.9M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
PRME
RR
Price
$3.02
$1.61
Analyst Decision
Buy
Hold
Analyst Count
6
2
Target Price
$7.56
$4.00
AVG Volume (30 Days)
3.1M
5.5M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
N/A
EPS
N/A
N/A
Revenue
$4,632,000.00
$5,045,000.00
Revenue This Year
$7.06
$75.68
Revenue Next Year
$47.01
$78.28
P/E Ratio
N/A
N/A
Revenue Growth
55.28
18.99
52 Week Low
$2.67
$1.30
52 Week High
$6.94
$7.43

Technical Indicators

Market Signals
Indicator
PRME
RR
Relative Strength Index (RSI) 42.71 41.08
Support Level $2.74 $1.30
Resistance Level $3.60 $2.21
Average True Range (ATR) 0.18 0.10
MACD -0.02 0.03
Stochastic Oscillator 46.00 55.00

Price Performance

Historical Comparison
PRME
RR

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About RR Richtech Robotics Inc. Class B

Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).

Share on Social Networks: